Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/23/2010US7838557 treating an allergic reaction by topically administering a therapeutically effective amount of an X-ray contrast medium comprising a triiodinated benzene moiety that is completely or partially substituted, and where contrast medium is a non-ionic or ionic monomer, a non-ionic or ionic dimer
11/23/2010US7838556 phenylpropyl ether or the phenylethyl ether; high affinity metabolically-stable analogs of GHB that have little or no affinity for GABA receptors, thus allowing for a therapeutic that acts cleanly through GHB receptors; fibromyalgia or chronic fatigue syndrome, narcolepsy, sleep disorders
11/23/2010US7838555 Useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and
11/23/2010US7838554 dyslipidemia; regulating lipid, lipoprotein, insulin, glucose levels in the blood; 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid; 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol; 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; 2,2,14,14-Tetramethyl-pentadecane-1,6,10,15-tetraol
11/23/2010US7838553 urinary incontinence, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, IBS, airway hyperactivity, epilepsy, stroke, Alzheimer's, Parkinson's, coronary artery disease, hair loss, baldness; 6-Chloro-2-(6,7-dichloro-3-hydroxy-2,2-dimethyl-chroman-4-yl)-benzo-[d]-isoxazol-3-one
11/23/2010US7838552 Compositions comprising nebivolol
11/23/2010US7838551 removing water of hydration from anhydrous form of docetaxel by azeotropic distillation, adding acid, filtering; (2R,3S) 4-acetoxy-2- alpha -benzoyloxy-5 beta -20-epoxy-1,7- beta -10- beta -tri-hydroxy-9-oxo-tax-11-en-13 alpha -il 3-tert-butoxy carbonylamino-2-hydroxy-3-phenylpropionate
11/23/2010US7838550 5-chloro-[N-3,3,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)propyl]thiophene-2-sulfonamide by reacting 2-amino-4,4,4-trifluoro-3-(trifluoromethyl)butan-1-ol and 5-chlorothiophene-2-sulfonyl chloride 4-methylmorpholine base; isopropyl acetate solvent; one step; beta amyloid inhibitor for Alzheimer's
11/23/2010US7838549 adding three or more sugars with high reproducibility, disulfide bond immobilized on protein-analyzing sensor chip; oligoethylene oxide group enables linker cmpd to minimize nonspecific hydrophobic interaction; metal-sulfur bond; 1,2-dithiolane on tri-branched amino acid attached to oligosaccharide; SPR
11/23/2010US7838548 antagonists; oligopeptide of N-(3-indolylacetyl)-L-isoleucine and glycine; IBD, sepsis, periodontal disease, mucositis, acne, cardiovascular disease, COPD, arthritis, cystic fibrosis, infections, ischemia/reperfusion, asthma, stroke, brain injuries, enterocolitis, bed sores, leprosy, atopic dermatitis
11/23/2010US7838547 obesity and diabetes; Melanin Concentrating Hormone inhibitors; antagonism of MCH1R;
11/23/2010US7838546 Crystal of substituted phenylalkanoic acid ester and process for producing the same
11/23/2010US7838545 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
11/23/2010US7838544 Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
11/23/2010US7838543 MCH receptor antagonists
11/23/2010US7838542 Bicyclic compositions and methods for modulating a kinase cascade
11/23/2010US7838541 Methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
11/23/2010US7838540 3-aminocarbonyl, 6-phenyl substituted pyridine-1-oxides as p38 kinase inhibitors
11/23/2010US7838539 Nicotine receptor agonists in stem cell and progenitor cell recruitment
11/23/2010US7838538 pyripyropene derivative; agricultural or horticultural insecticide;
11/23/2010US7838537 Viral polymerase inhibitors
11/23/2010US7838536 delivers zinc to cancer cells or zinc chelation within the cancer cells using the unbound ligand; bioavailability; with texaphyrin metal complex;
11/23/2010US7838535 Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/23/2010US7838534 muscarinic M3-receptor; respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD); 3-[(3-fluorophenyl)-(3,4,5-trifluorobenzyl)carbamoyloxy]-1-(2-oxo-2-thiophen-2-ylethyl)-1-azoniabicyclo[2.2.2]octane bromide; inhalation
11/23/2010US7838533 Azaindole inhibitors of MTP and ApoB
11/23/2010US7838532 aqueous solution of levofloxacin or ofloxacin and a divalent or trivalent cation such as magnesium chloride, wherein the solution is suitable for inhalation into a lung; treatment of respiratory tract and pulmonary infections
11/23/2010US7838531 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
11/23/2010US7838530 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
11/23/2010US7838529 type II diabetes mellitus and obesity; dipeptidylpeptidase-IV (DPP-IV) inhibitor; 1-[2-(2-formylaminophenyl)-2-oxoethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine (xanthine=3,7-dihydro-purine-2,6-dione)
11/23/2010US7838528 Substituted bicyclic 8-pyrrolidinoxanthines, methods for their production, pharmaceutical formulations and their use
11/23/2010US7838527 Methods of treating cancer and related methods
11/23/2010US7838526 essential tremor can effectively be treated with high doses of Riboflavin (vitamin B2), either on its own or coupled with one or more other B vitamins and/or coenzyme Q10 (CoQ10)
11/23/2010US7838525 modulators of glucose metabolism, GPCR, RUP3; metabolic disorders and complications thereof such as diabetes and obesity; 4-[5-Cyano-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester
11/23/2010US7838524 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
11/23/2010US7838523 [5-(Pyridin-2-ylamino)-6-oxo-1,6-dihydro-pyridin-3-yl]-(3-amido)-benzene derivatives; anticarcinogenic, antiproliferative, antiallergen, and antiinflammatory agents; lymphoma, leukemia, autoimmune diseases; Bruton's tyrosine kinase inhibitors
11/23/2010US7838522 with polyglycolized glyceride (macrogol glyceride); Gelucires"; multiple sclerosis, asthma, scleroderma, endometriosis; 1,3-benzothiazol-2(3H)-ylidene{2-[(1,4-dimethylpiperazin-2-yl)methoxy]pyrimidin-4-yl}acetonitrile; adding to melt as powder under stirring resulting in homogeneous molten dispersion
11/23/2010US7838521 phosphodiesterase PDE4 inhibitor; preparing claimed 3-(dialkoxy)phenyl-4-aminopyran intermediate from the claimed 4-oxo compound starting with hydrobromination of the corresponding phenylacetylene; antiinflammatory for airways and skin; respiratory; bronchodilator
11/23/2010US7838520 Inhibitors of histone deacetylase
11/23/2010US7838519 Maytansinoid analogs as antitumor agents
11/23/2010US7838518 1-(4-methoxynaphthalene-1-sulfonyl)-2,3-dihydro-1H-indole-3-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]amide; selective affinity for 5-HT6 receptor; psychosis, schizophrenia, depression, neurological disorders, cognitive enhancement, Parkinson's disease, ALS, Alzheimer's, Huntington's disease
11/23/2010US7838517 Compounds useful as protein kinase inhibitors
11/23/2010US7838516 for the estrogen receptor alpha-subtype; contraceptive; hot flushes, osteoporosis; 7 alpha-ethyl-15 beta-methyl-19-nor-17 alpha -pregna-1,3,5(10)-trien-20-yne-3,17 beta-diol
11/23/2010US7838515 injection formulation comprising vecuronium and saccharin, dissolved or dispersed in an aqueous solution or an aqueous dispersion, wherein there is a molar excess of saccharin to quaternary ammonium groups of vecuronium compound; muscle relaxants
11/23/2010US7838513 Anti-cancer therapy comprising an H2-blocker, at least one antiinflammatory agent and a cytotoxic agent
11/23/2010US7838512 enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity; pancreatic cancer treatment
11/23/2010US7838511 With a phospholipid such as dipalmitoyl phosphatidylcholine, and an antiinflammatory drug such as a nonsteroidal, anti-inflammatory drug (NSAID) such as celecoxib
11/23/2010US7838510 Biomaterials based on hyaluronic acid for the anti-angiogenic therapy in the treatment of tumors
11/23/2010US7838509 Methods and compositions to improve germ cell and embryo survival and function
11/23/2010US7838508 such as 2-chloro-9-(4-thio-alpha-L-xylofuranosyl)adenine for treatment of leukemia; anticancer agents
11/23/2010US7838506 nonpeptidic inhibitors of cathepsin G; genetic diseases, degenerative diseases, DNA damages, neoplasia and/or skin diseases; DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing
11/23/2010US7838505 using hybrid Hepatocyte Growth Factor (HGF) construct for prevention and treatment of ischemic and liver disorders
11/23/2010US7838504 Reducing flavivirus or Hepatitis virus replication in vitro or vivo by inhibiting activity of a microRNA; administering an antisense oligonucleotide complementary to microR-122
11/23/2010US7838503 Methods for extending the replicative lifespan of cells
11/23/2010US7838500 treating metabolic disorders such as diabetes, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, insulin resistance, and metabolic syndrome
11/23/2010US7838499 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-(2-methoxyethoxy)ethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; for treating diseases assoicated with sodium glucose co-transporter inhibition (SGLT) such as diabetes, hyperglycemia, insulin resistance, metabolic syndrome, atherosclerosis
11/23/2010US7838498 Benzylic glycoside derivatives and methods of use
11/23/2010US7838495 Compositions and methods of use of EPB1, and ErbB3 binding protein
11/23/2010US7838489 tumor necrosis factor (TNF) receptors, immunoglobuin fusion proteins; anti-tumor necrosis factor antibodies; Crohn's disease, and acute and chronic immune diseases associated with transplantation
11/23/2010US7838279 Production of isoprenoids
11/23/2010US7838247 determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1; diagnosing Alzheimer's disease
11/23/2010US7838122 biodegradable hydrogel FGF-beta mimetic; PEG-dihydrazide crosslinking agent for a desamino-tyrosyl-tyrosine dipeptide or polypeptides thereof; implantable resorbable medical device; wound healing; the water soluble polymer can also be polysaccharide, polyvinyl alcohol or poly(N-methyl pyrrolidone)
11/23/2010US7838055 microcrystallization of xylitol and maltitol via spraying liquid feed thereof, evaporating solvent, conditioning, milling; for use in confectionery, foodstuffs, oral hygiene products and pharmaceuticals and dietetic
11/23/2010US7838050 Cytokine modulators and related method of use
11/23/2010US7838042 side effect reduction; for nut and dairy allergies
11/23/2010US7838037 of active ingredients for topical use; dissolving active ingredient in ethyl acetate with acrylate copolymer; double-layer and triple-layer microcapsules; oxidation resistance; storage stability
11/23/2010US7838032 An expectorant drug delivery dosage forms comprises a sustained release portion and an immediate release portion; relieving from bronchial mucus accumulation
11/23/2010US7838027 Pantoprazole multiparticulate formulations
11/23/2010US7838024 Multicompartment drug delivery system for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/23/2010US7838023 Ethanamine, 2-L[5-oxido-4-phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]-N,N-bis[2-[[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]ethyl]-; cardiovascular diseases; inhibiting platelet aggregation, platelet adhesion caused by the exposure of blood to a medical device; abnormal cell proliferation
11/23/2010US7838020 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor
11/23/2010US7838011 a transdermal mixture of collagen, elastin, sphingoside, cerebroside and botulinum toxin
11/23/2010US7837998 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
11/23/2010US7837995 Anticancer agents; low dosage; side effect reduction
11/23/2010US7837987 Fusion using polyoxyalkylene glycol
11/23/2010US7837986 Protein-based polymer tissue adhesives for medical use
11/23/2010US7837883 Biocides and apparatus
11/23/2010CA2799515A1 Delayed release rasagiline formulation
11/23/2010CA2727899A1 Delayed release rasagiline formulation
11/23/2010CA2599860C 1, 2, 4-triazole derivatives and their use as oxytocin antagonists
11/23/2010CA2563022C Process for preparing 1,3-dioxolane derivatives
11/23/2010CA2547378C Edible compositions which are adapted for use by a companion animal
11/23/2010CA2529470C Process for controlling crystal structure of risedronate
11/23/2010CA2516642C Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
11/23/2010CA2503223C Meso-substituted porphyrins
11/23/2010CA2496295C Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
11/23/2010CA2487489C Mitotic kinesin inhibitors
11/23/2010CA2480776C Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
11/23/2010CA2478094C Methods of inducing terminal differentiation
11/23/2010CA2462085C Cytotoxic agents
11/23/2010CA2459380C Reverse hydroxamic acid derivatives
11/23/2010CA2457114C Device for the administration of an active agent to the human skin
11/23/2010CA2449822C Reduction of hair growth
11/23/2010CA2444529C Micellar drug delivery systems for hydrophobic drugs
11/23/2010CA2440014C Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
11/23/2010CA2438870C Novel inhibitors of formation of advanced glycation endproducts (ages)
11/23/2010CA2435414C Solid phase dispersion of quinolone- or naphthyridonecarboxylic acids
11/23/2010CA2434775C Compounds for use in the treatment of skin conditions
11/23/2010CA2433585C Pharmaceutical compositions containing donepezil hydrochloride
11/23/2010CA2423192C 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
11/23/2010CA2385150C Vascular coating composition
1 ... 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 ... 7860